| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 86941 |
(S)-N-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYL)-6-(METHYL(3-(PIPERAZIN-1-YL)PROPYL)AMINO)QUINOLINE-4-CARBOXAMIDE |
116 |
wyh |
2024-11-22 |
| 86942 |
DOTA(Tris)-EA-TEG-NH2-CBZ DOTA(Tris)-乙胺(EA)偶联四甘醇(TEG) |
210 |
zcy |
2024-11-22 |
| 86943 |
DOTA-octreotide,大环配体奥曲肽 |
133 |
zyl |
2024-11-22 |
| 86944 |
N2-Acetyl-N6-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-L-lysyl-L-prolyl-N2-methyl-L-arginyl-L-arginyl-L-prolyl-L-tyrosyl-3-methyl-L-valyl-L-leucine |
94 |
wyh |
2024-11-22 |
| 86945 |
DOTA-Ts29.2 DOTA偶联单克隆抗体Ts29.2 |
121 |
zcy |
2024-11-22 |
| 86946 |
DOTA-FAMP α螺旋肽偶联DOTA大环配体 |
117 |
zcy |
2024-11-22 |
| 86947 |
DOTA-NT8-13(靶向NTR1) |
121 |
zcy |
2024-11-22 |
| 86948 |
DOTA Conjugated JM#21 derivative 7 ；3033865-40-3 |
131 |
wyh |
2024-11-22 |
| 86949 |
4-Aminobutyl-DOTA-tris(t-butyl ester) Hexafluorophosphate |
95 |
wyh |
2024-11-22 |
| 86950 |
L-Threonine, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (2→7)-disulfide |
92 |
wyh |
2024-11-22 |
| 86951 |
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 1-(2,5-dioxo-1-pyrrolidinyl) ester |
99 |
wyh |
2024-11-22 |
| 86952 |
DOTA-MC1RL 1，4，7，10-四氮杂环十二烷-1，4，7，10-四乙酸缀合MC1R特异性支架 |
133 |
zcy |
2024-11-22 |
| 86953 |
钆布醇杂质20 ；229312-34-9 |
144 |
wyh |
2024-11-22 |
| 86954 |
DOTA-[Nle]-cCCK 科研定制 |
144 |
zcy |
2024-11-22 |
| 86955 |
DOTA-(COOt-Bu)3-CH2-Alkynyl ；1189194-64-6 |
98 |
wyh |
2024-11-22 |
| 86956 |
FITC-PEG2-TATE ；1027160-33-3 |
119 |
wyh |
2024-11-22 |
| 86957 |
DOTA-peg4-LLP2AVLA-4 齐岳定制 |
120 |
zcy |
2024-11-22 |
| 86958 |
蛙皮素肽功能化金纳米颗粒 BBN-AuNPs |
115 |
zcy |
2024-11-22 |
| 86959 |
RGD-DOTA的结构特点 |
122 |
wyh |
2024-11-22 |
| 86960 |
DOTA tris(TBE)-amido-dPEG-bromoacetamide |
103 |
wyh |
2024-11-22 |
| 86961 |
DOTA-PEG-OPSS-AuNP DOTA-PEG-邻吡啶基二硫化物修饰纳米金纳米粒子 |
135 |
zcy |
2024-11-22 |
| 86962 |
DOTA-PEG(23)-MAL*2TFA |
105 |
wyh |
2024-11-22 |
| 86963 |
DOTA偶联PSMA抑制剂 DOTA-PSMA |
116 |
zcy |
2024-11-22 |
| 86964 |
DOTA-PEG(11)-bromoacetamide*2TFA |
119 |
wyh |
2024-11-22 |
| 86965 |
Gn-PAMAM-(TmDOTA(-))(x)(其中n = 1-4，x = 6-39) 齐岳定制 |
128 |
zcy |
2024-11-22 |
| 86966 |
DOTA-(AF)SAv 1，4，7，10-四氮杂环十二烷-N，N′，N″，N″-四乙酸(DOTA)-(AF)SAv |
114 |
zcy |
2024-11-22 |
| 86967 |
PAMAM-DOTA DOTA缀合PAMAM树状大分子 |
156 |
zcy |
2024-11-22 |
| 86968 |
1374865-01-6；10-[2-[[3-(11,12-二脱氢二苯并[B,F]氮杂环辛-5(6H)-基)-3-氧代丙基]氨基]-2-氧代乙基]-1,4,7,10-四氮杂环十二烷-1,4,7-三乙酸 |
130 |
wyh |
2024-11-22 |
| 86969 |
DOTA-(D-Glu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 齐岳定制 |
131 |
zcy |
2024-11-22 |
| 86970 |
DOTA唑来膦酸盐 ，1908409-18-6 ，DOTA Zoledronate |
123 |
wyh |
2024-11-22 |
| 86971 |
DOTA-C225-AuNPs DOTA修饰西妥昔单抗偶联金纳米颗粒 |
173 |
zcy |
2024-11-22 |
| 86972 |
FAP结合肽大环化合物；2581741-18-4 |
190 |
wyh |
2024-11-22 |
| 86973 |
DOTA-DGlu-Ala-Tyr DOTA偶联受体特异性肽 |
108 |
zcy |
2024-11-22 |
| 86974 |
三（叔丁氧羰基甲基）DOTA氢溴酸盐；137076-54-1 |
117 |
wyh |
2024-11-22 |
| 86975 |
DOTA-h173 双功能螯合剂DOTA偶联h173 |
112 |
zcy |
2024-11-22 |
| 86976 |
DOTA-四聚乙二醇-二苯并环辛炔；DOTA-PEG4-DBCO |
124 |
wyh |
2024-11-22 |
| 86977 |
BSH-3R-DOTA-(64)Cu BSH-3R偶联1，4，7，10-四氮杂环十二烷-1，4，7，10-四乙酸(DOTA) |
128 |
zcy |
2024-11-22 |
| 86978 |
DOTA-三(酸) - 酰氨基-DPEG(R)23-马来酰亚胺 |
138 |
wyh |
2024-11-22 |
| 86979 |
十六烷基-1，4，7，10-四氮杂环十二烷-四乙酸-苯甲酸酯 DOTA-HB |
106 |
zcy |
2024-11-22 |
| 86980 |
DOTA (POL-D)缀合物 |
127 |
zcy |
2024-11-22 |
| 86981 |
DOTA-3-iodo-Tyr3-octreotate DOTA-3-碘-Tyr3-辛酸酯 |
107 |
zcy |
2024-11-22 |
| 86982 |
(177LU)-DOTA-FAPI-04 ；2374782-97-3 |
125 |
wyh |
2024-11-22 |
| 86983 |
DOTA-NT20.3 1, 4, 7, 10-四氮杂环十二烷-1, 4, 7, 10-四乙酸-NT-20.3 |
109 |
zcy |
2024-11-22 |
| 86984 |
DOTA-去乙酰秋水仙碱(68Ga-1) |
107 |
zcy |
2024-11-22 |
| 86985 |
DOTA-[NaI(3)]-奥曲肽 DOTA-NOC |
120 |
zcy |
2024-11-22 |
齐岳微信公众号
官方微信
库存查询